Antigen-specific human B-cell responses: Modulation by immunoregulatory T-cell subsets

1983 ◽  
Vol 82 (2) ◽  
pp. 223-231 ◽  
Author(s):  
Marion Peters ◽  
Anthony S. Fauci
1998 ◽  
Vol 72 (7) ◽  
pp. 6138-6145 ◽  
Author(s):  
Narendra Chirmule ◽  
Joseph V. Hughes ◽  
Guang-Ping Gao ◽  
Steven E. Raper ◽  
James M. Wilson

ABSTRACT Adenovirus vectors delivered to lung are being considered in the treatment of cystic fibrosis (CF). Vectors from which E1 has been deleted elicit T- and B-cell responses which confound their use in the treatment of chronic diseases such as CF. In this study, we directly compare the biology of an adenovirus vector from which E1 has been deleted to that of one from which E1 and E4 have been deleted, following intratracheal instillation into mouse and nonhuman primate lung. Evaluation of the E1 deletion vector in C57BL/6 mice demonstrated dose-dependent activation of both CD4 T cells (i.e., TH1 and TH2 subsets) and neutralizing antibodies to viral capsid proteins. Deletion of E4 and E1 had little impact on the CD4 T-cell proliferative response and cytolytic activity of CD8 T cells against target cells expressing viral antigens. Analysis of T-cell subsets from mice exposed to the vector from which E1 and E4 had been deleted demonstrated preservation of TH1 responses with markedly diminished TH2 responses compared to the vector with the deletion of E1. This effect was associated with reduced TH2-dependent immunoglobulin isotypes and markedly diminished neutralizing antibodies. Similar results were obtained in nonhuman primates. These studies indicate that the vector genotype can modify B-cell responses by differential activation of TH1 subsets. Diminished humoral immunity, as was observed with the E1 and E4 deletion vectors in lung, is indeed desired in applications of gene therapy where readministration of the vector is necessary.


2000 ◽  
Vol 164 (8) ◽  
pp. 4097-4104 ◽  
Author(s):  
Shinji Morimoto ◽  
Yumiko Kanno ◽  
Yuetsu Tanaka ◽  
Yoshiaki Tokano ◽  
Hiroshi Hashimoto ◽  
...  

2018 ◽  
Vol 200 (10) ◽  
pp. 3383-3396 ◽  
Author(s):  
Kuan Y. Wong ◽  
Rebecca Baron ◽  
Therese A. Seldon ◽  
Martina L. Jones ◽  
Alison M. Rice ◽  
...  

Author(s):  
Felix G. Delgado ◽  
Karina I. Torres ◽  
Jaime E. Castellanos ◽  
Consuelo Romero-Sánchez ◽  
Etienne Simon-Lorière ◽  
...  

The high level of dengue virus (DENV) seroprevalence in areas where Zika virus (ZIKV) is circulating and the cross-reactivity between these two viruses have raised concerns on the risk of increased ZIKV disease severity for patients with a history of previous DENV infection. To determine the role of DENV pre-immunity in ZIKV infection, we analysed the T and B cell responses against ZIKV in donors with or without previous DENV infection. Using PBMCs from donors living in an endemic area in Colombia, we have identified, by interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay, most of the immunodominant ZIKV T-cell epitopes in the non-structural proteins NS1, NS3 and NS5. Analyses of the T and B-cell responses in the same donors revealed a stronger T-cell response against peptides conserved between DENV and ZIKV, with a higher level of ZIKV-neutralizing antibodies in DENV-immune donors, in comparison with DENV-naïve donors. Strikingly, the potential for antibody mediated enhancement of ZIKV infection was reduced in donors with sequential DENV and ZIKV infection in comparison with donors with DENV infection only. Altogether, these data suggest that individuals with DENV immunity present improved immune responses against ZIKV.


10.1038/ni947 ◽  
2003 ◽  
Vol 4 (8) ◽  
pp. 765-772 ◽  
Author(s):  
Tak W Mak ◽  
Arda Shahinian ◽  
Steve K Yoshinaga ◽  
Andrew Wakeham ◽  
Louis-Martin Boucher ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document